Vanguard Group
IPSC icon

Vanguard Group’s Century Therapeutics IPSC Stock Holding History

Vanguard Group’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.09M Hold
2,103,869
– – ﹤0.01% 3546
2025
Q3 		$1.05M Sell
2,103,869
-6,213
-0.3% -$3.35K ﹤0.01% 3775
2025
Q2 		$1.18M Sell
2,110,082
-267,412
-11% -$143K ﹤0.01% 3701
2025
Q1 		$1.13M Sell
2,377,494
-4,213
-0.2% -$3.17K ﹤0.01% 3675
2024
Q4 		$2.41M Sell
2,381,707
-93,508
-4% -$127K ﹤0.01% 3503
2024
Q3 		$4.23M Buy
2,475,215
+743,082
+43% +$1.46M ﹤0.01% 3331
2024
Q2 		$4.42M Buy
1,732,133
+593,480
+52% +$1.88M ﹤0.01% 3308
2024
Q1 		$4.76M Buy
1,138,653
+14,000
+1% +$59.3K ﹤0.01% 3317
2023
Q4 		$3.73M Buy
1,124,653
+5,483
+0.5% +$9.99K ﹤0.01% 3395
2023
Q3 		$2.24M Sell
1,119,170
-28,555
-2% -$76K ﹤0.01% 3542
2023
Q2 		$3.63M Buy
1,147,725
+36,656
+3% +$118K ﹤0.01% 3450
2023
Q1 		$3.86M Buy
1,111,069
+33,597
+3% +$148K ﹤0.01% 3421
2022
Q4 		$5.53M Buy
1,077,472
+8,784
+0.8% +$82.9K ﹤0.01% 3259
2022
Q3 		$10.6M Buy
1,068,688
+161,713
+18% +$1.7M ﹤0.01% 2934
2022
Q2 		$7.62M Buy
906,975
+87,213
+11% +$855K ﹤0.01% 3136
2022
Q1 		$10.3M Buy
819,762
+271,760
+50% +$3.6M ﹤0.01% 3131
2021
Q4 		$8.69M Buy
548,002
+113,392
+26% +$2.13M ﹤0.01% 3297
2021
Q3 		$10.9M Buy
434,610
+404,610
+1,349% +$11M ﹤0.01% 3186
2021
Q2 		$880K Buy
+30,000
New +$761K ﹤0.01% 4175

Other funds holding IPSC

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

Vanguard Group's IPSC Position: Q4 2025 in Review

Vanguard Group held its Century Therapeutics (IPSC) position steady in Q4 2025 at 2,103,869 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #3546.

Vanguard Group first reported a position in IPSC in Q2 2021 and has held it in 19 quarters since. The position peaked at $10.9M in Q3 2021. 47 funds tracked by Wall St. Rank hold IPSC as of Q4 2025.

  • Vanguard Group held 2,103,869 shares of Century Therapeutics worth $2.09M as of Q4 2025.
  • Vanguard Group left its Century Therapeutics share count unchanged in Q4 2025.
  • Century Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3546 holding.
  • Vanguard Group first reported a position in Century Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Vanguard Group's Century Therapeutics position peaked at $10.9M in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Century Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.